Journal of Pharmaceutical Research
DOI: 10.18579/jopcr/v25.i3.129
Year: 2026, Volume: 25, Issue: 3, Pages: 184-190
Original Article
Akanksha A Borhade1*, Pravin R Dighe1
1Department of Pharmaceutical Chemistry, S.M.B.T College of Pharmacy, Nashik-422403, Maharashtra, India
*Corresponding Author
Email: [email protected]
A simple, rapid, precise, accurate, and robust reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the quantitative determination of finerenone in bulk drug substance and pharmaceutical tablet formulation. Chromatographic separation was achieved on a C18 column employing an isocratic mobile phase composed of acetonitrile and 10 mM ammonium dihydrogen phosphate buffer (pH 4.5) at a flow rate of 1.0 mL/min, with UV detection at 238 nm. Finerenone exhibited a retention time of 7.24 min. The method was validated as per ICH Q2(R2) guidelines with respect to system suitability, specificity, linearity, accuracy, precision, robustness, and solution stability. Linearity was demonstrated over a concentration range of 50–150% of the working concentration (100.52–301.56 µg/mL), with a correlation coefficient of 1.00. Recovery studies at three spike levels (50%, 100%, and 150%) yielded mean percent recovery of 101.1% (%RSD 0.45), indicating excellent accuracy. Method precision studies showed %RSD of 0.27%, well within the NMT 2.0% acceptance criterion. Standard and sample solutions were stable for up to 65 hours and 58 hours, respectively, at 10°C. Specificity evaluation confirmed no interference from placebo excipients or known process-related impurities (acid impurity, aromatization impurity, dimethyl impurity). The validated method was successfully applied to the assay of marketed tablets and is suitable for routine quality control analysis of finerenone in pharmaceutical manufacturing environments.
Keywords: Finerenone, HPLC, Method validation, ICH Q2(R2), Analytical method development, Mineralocorticoid receptor antagonist
1. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clinical Science. 2022; 136 (12). Available from: https://doi.org/10.1042/cs20220212
2. Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Review of Clinical Pharmacology. 2022; 15 (5). Available from: https://doi.org/10.1080/17512433.2022.2094770
3. Ramadan MM, Alajmi S, Aldouseri J, Alajmi M, Tello EA, Mahdi AO, et al. Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist. Cureus. 2025; 17 (7). Available from: https://doi.org/10.7759/cureus.87706
4. Georgianos PI, Agarwal R. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. American Journal of Hypertension. 2023; 36 (3). Available from: https://doi.org/10.1093/ajh/hpac124
5. Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Frontiers in Cardiovascular Medicine. 2024; 11 Available from: https://doi.org/10.3389/fcvm.2024.1476029
6. Kim DL, Song YS, Kim SJ. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease. Endocrinology and Metabolism. 2023; 38 (1). Available from: https://doi.org/10.3803/enm.2022.1629
7. Marzolla V, Infante M, Armani A, Rizzo M, Caprio M. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Expert Opinion on Drug Safety. 2022; 21 (9). Available from: https://doi.org/10.1080/14740338.2022.2130889
8. Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgraduate Medicine. 2023; 135 (3). Available from: https://doi.org/10.1080/00325481.2022.2060598
9. Memon AAQ, Iqbal S. Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure. Global Journal of Medical, Pharmaceutical, and Biomedical Update. 2022; 17 Available from: https://doi.org/10.25259/gjmpbu_25_2022
10. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2021; 385 (24). Available from: https://doi.org/10.1056/nejmoa2110956
11. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020; 383 (23). Available from: https://doi.org/10.1056/nejmoa2025845
12. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022; 43 (6). Available from: https://doi.org/10.1093/eurheartj/ehab777
13. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022; 45 (12). Available from: https://doi.org/10.2337/figshare.20289009.v1
14. Fathima H, Pasha M, Khaleel M. Estimation and Validation of Finerenone in Dosage Form and in Bulk Drug by Spectrophotometric Method. Asian Journal of Research in Chemistry. 2023; Available from: https://doi.org/10.52711/0974-4150.2023.00033
15. Parmar I, Patel YA. Recent method development by analytical techniques of new FDA approved drugs in 2021. International Journal of Current Pharmaceutical Research. 2022; 14 (3). Available from: https://doi.org/10.22159/ijcpr.2022v14i3.1975
16. Jilla L, Aleti RR, Erusalagandi RS. A new RP-HPLC method development, validation and stability indicating for the estimation of finerenone in bulk and pharmaceutical dosage forms. International Journal of All Research Education and Scientific Methods. 2023; 11(4): 1342-1349.
17. Mohammed A, Arsalan M, Jabeen M, Begum H. Liquid chromatography method development and validation for the quantitative determination of finerenone in bulk drug and pharmaceutical formulation. TIJER — International Research Journal. 2023; 10 (6). Available from: https://tijer.org/TIJER/papers/TIJER2306209.pdf
18. Chepyala S, Medidi S, Malik JK. Development of a Robust and Reliable RP-HPLC Method for the Estimation of Finerenone in Tablet Dosage Form. International Journal of Drug Delivery Technology. 2024; 14 (02). Available from: https://doi.org/10.25258/ijddt.14.2.15
19. Illendula S, Samiha SK, Naik AB, Suresh CV, Rao KN. Development and validation of a new analytical RP-HPLC method for the estimation of finerenone in bulk and marketed formulation. World Journal of Pharmaceutical and Life Sciences. 2024; 10 (2). Available from: https://www.wjpls.org/home/article_abstract/3196
20. Mirjapuram J, Sammaiah G. Analytical method development and validation for simultaneous estimation of loratadine and pseudoephedrine in bulk and tablet dosage form by RP HPLC method. International Journal of Allied Medical Sciences and Clinical Research. 2023; 11 (2). Available from: https://doi.org/10.61096/ijamscr.v11.iss2.2023.210-218
21. Marie AA, Yassin MG, Elshenawy EA. Stability indicating RP-HPLC method for estimation of finerenone and its related substances in new dosage form. Scientific Reports. 2025; 15 (1). Available from: https://doi.org/10.1038/s41598-025-07166-4
22. Imran SJ, Kini SG, Kumar V, Sonawane B, Chaudhari J, Warde S. Validated stability indicating reversed-phase high-performance liquid chromatography (RP-HPLC) for the estimation of FINERENONE in Pharmaceutical tablet dosage form. International Journal of Innovative Research in Technology. 2024; 11 (2). Available from: https://doi.org/10.21203/rs.3.rs-2984018/v1
23. Murugesan A, Mukthinuthalapati Mathrusri A. Forced Degradation Studies for Estimation of Finerenone by RP-HPLC Method. Acta Scientific Pharmaceutical Sciences. 2021; Available from: https://doi.org/10.31080/asps.2021.05.0818
24. Rohde G, Loewen S, Heinig R. a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma. Journal of Chromatography B. 2021; 1172 Available from: https://doi.org/10.1016/j.jchromb.2021.122643
25. Somase K, Rishipathak D. Finerenone API Estimation Using RP-HPLC Technique and LC-MS Characterization of its Degradation Products. Oriental Journal Of Chemistry. 2025; 41 (2). Available from: https://doi.org/10.13005/ojc/410222
26. Alsharif ST, Alaqel SI, Almalki AH, Almalki FA, Albogami AM, Alharbi MA. A fluorescence chemo sensor approach for determination of finerenone in pharmaceutical formulation and human plasma: Method development and validation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2024; 309 Available from: https://doi.org/10.1016/j.saa.2024.123836
27. Illendula S, Samiha SK, Naik AB, Suresh CV, Rao KN. Bioanalytical method development and validation for estimation of finerenone in spiked human plasma using RP-HPLC technique and application of statistical tool. Biosciences Biotechnology Research Asia. 2025; 22 (3). Available from: https://doi.org/10.13005/bbra/3427
28. Lakshmi Kalyani B, Yesvanti S, Sahasrika S, Likhitha Reddy M, Roshini B. Comprehensive insights into finerenone: recent HPLC advancements and clinical prospects. International Journal of Research and Analytical Reviews. 2023; 10 (4). Available from: https://ijrar.org/papers/IJRAR23D1246.pdf
29. International Council for Harmonisation (ICH). Validation of Analytical Procedures Q2(R2). ICH Harmonised Guideline. Geneva: ICH. Available from: https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf, 2023
30. United States Pharmacopeia (USP) 2024. General Chapter <621> Chromatography. 2nd Supplement to USP 47. United States Pharmacopeia Convention. Rockville. 2024.
31. International Council for Harmonisation (ICH). Impurities in New Drug Products Q3B(R2). ICH Harmonised Guideline. Geneva: ICH. Available from: https://database.ich.org/sites/default/files/Q3B(R2)%20Guideline.pdf, 2006
32. International Council for Harmonisation (ICH). Analytical Procedure Development Q14. ICH Harmonised Guideline. Geneva: ICH. Available from: https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1130.pdf, 2023
33. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. Journal of Pharmaceutical and Biomedical Analysis. 2001; 24 (5-6). Available from: https://doi.org/10.1016/s0731-7085(00)00529-x
34. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 2010; (3rd Edition). Available from: https://doi.org/10.1002/9780470508183
35. Metkari VB, Gade V. Method development and validation of finerenone by RP-HPLC method. International Journal of Innovative Research in Technology. 2024; 11 (2). Available from: https://ijirt.org/publishedpaper/IJIRT166111_PAPER.pdf
36. Naazneen S. An Isocratic RP-HPLC Method Development and Validation for the Quantitative Estimation of Finerenone in Solid Dosage Forms. International Journal For Multidisciplinary Research. 2024; 6 (3). Available from: https://doi.org/10.36948/ijfmr.2024.v06i03.23098
37. Varade MM, Patil PR, Jadhav RG. RP-HPLC method development and validation of finerenone in bulk drug and its formulations. GSC Biological and Pharmaceutical Sciences. 2024; 27 (1). Available from: https://doi.org/10.30574/gscbps.2024.27.1.0128
38. Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo. European Journal of Drug Metabolism and Pharmacokinetics. 2018; 43 (6). Available from: https://doi.org/10.1007/s13318-018-0483-9
39. Heinig R, Eissing T. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. Clinical Pharmacokinetics. 2023; 62 (12). Available from: https://doi.org/10.1007/s40262-023-01312-9
40. Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first‐in‐man and relative bioavailability studies. Fundamental & Clinical Pharmacology. 2016; 30 (2). Available from: https://doi.org/10.1111/fcp.12170
41. Eissing T, Ploeger B, Winkler MG, Joseph A, Gerisch M, Scheerer MF, et al. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism. 2024; 26 (3). Available from: https://doi.org/10.1111/dom.15387
42. Nyamagoud SB, Swamy AH, Hiremath J, Athreya BJ, Raj S, Hegde M, et al. Finerenone as a New Potent Resistant Hypertension Agent: A Review. International Journal of Pharmaceutical Investigation. 2023; 14 (1). Available from: https://doi.org/10.5530/ijpi.14.1.2
43. Pradhan A, Tripathi UC. Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease. The Egyptian Heart Journal. 2024; 76 (1). Available from: https://doi.org/10.1186/s43044-024-00586-z
44. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022; 43 (6). Available from: https://doi.org/10.1093/eurheartj/ehab777
45. Parrinello CM, Bhatt DL. Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022; 16 (10). Available from: https://doi.org/10.1016/j.dsx.2022.102638
© 2026 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Subscribe now for latest articles and news.
